Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung CancerPrimo N. Lara, Giorgio V. Scagliotti, Mark J. McKeage et al.|Journal of Clinical Oncology|2011Cited by 320
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinomaChan-Young Ock, Dae Seog Heo|Oncotarget|2017Cited by 87
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor CapmatinibSeulki Kim, Dae Seog Heo|Cancer Research and Treatment|2018Cited by 66
Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patientsShin Hye Yoo, Dae Seog Heo|Scientific Reports|2019Cited by 46
Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinomaRyul Kim, Dae Seog Heo|World Journal of Gastroenterology|2016Cited by 31